Company Overview of Avaxia Biologics, Inc.
Avaxia Biologics, Inc., a biotechnology company, develops oral antibody therapeutics. Its product pipeline comprises antibody drugs for inflammatory bowel diseases, radiation mitigations, celiac diseases, obesity and diabetes, and oral mucositis. Avaxia Biologics, Inc. has a strategic collaboration with Courtagen Life Sciences, Inc. The company was founded in 2005 and is based in Lexington, Massachusetts.
128 Spring Street
Lexington, MA 02421
Founded in 2005
Key Executives for Avaxia Biologics, Inc.
Founder and Chief Executive Officer
Vice President of Technical Operations
Vice President of Product Development
Compensation as of Fiscal Year 2014.
Avaxia Biologics, Inc. Key Developments
Avaxia Biologics, Inc. Receives FDA Orphan Drug Designation for AVX-470 for the Treatment of Pediatric Ulcerative Colitis
Nov 21 14
Avaxia Biologics, Inc. announced that the US Food and Drug Administration (FDA) granted Orphan Drug Designation to AVX-470 for the treatment of pediatric ulcerative colitis. AVX-470 is a gut-targeted anti-TNF antibody, which earlier this year successfully completed a Phase 1b clinical trial in adults with active ulcerative colitis. Pediatric ulcerative colitis (UC) is a serious chronic inflammatory disease of the colon. As with adult patients, children with acute UC have symptoms of rectal bleeding, diarrhea, weight loss, abdominal pain, and fever. In addition, pediatric UC patients face impaired growth and delayed puberty, as well as challenges to self-image and quality of life during the critical childhood years. Most pediatric UC patients experience more severe disease than adults, and the disease may progress more quickly in children. If drug therapy fails to control the disease, the only treatment is surgical removal of the colon (colectomy). The US Orphan Drug Act is intended to assist and encourage companies to develop safe and effective therapies for the treatment of rare diseases and disorders that affect fewer than 200,000 individuals within the United States. Among other benefits, Orphan Drug Designation confers a seven-year term of market exclusivity upon FDA approval. AVX-470 is the first gut-targeted anti-TNF antibody in clinical development. The lead indication is inflammatory bowel disease (IBD), a serious disease involving chronic inflammation of the intestinal tract. Currently marketed anti-TNF drugs are highly effective for the treatment of IBD. However, despite their success, these drugs have two significant drawbacks. One is that they must be infused or injected, whereas patients prefer oral medications. More importantly, they cause rare but serious side effects, such as risk of serious infection, because they dampen the immune system throughout the body, not just in the intestines where the disease occurs. As a result, these drugs are used mostly as a second- or third-line therapy, despite evidence that earlier use may improve patient outcomes. In contrast, AVX-470 is an orally administered antibody therapeutic that targets the gut, potentially improving safety and efficacy over existing anti-TNF therapies. Avaxia believes that AVX-470 has the potential to become a first-line therapy that transforms the treatment of IBD.
Avaxia Biologics, Inc. Presents at Boston Biotech NY/NJ CEO Conference, Nov-12-2014 11:25 AM
Oct 27 14
Avaxia Biologics, Inc. Presents at Boston Biotech NY/NJ CEO Conference, Nov-12-2014 11:25 AM. Venue: Apella, 450 East 29th Street, New York, New York, United States. Speakers: Barbara S. Fox, Founder and Chief Executive Officer.
Avaxia Biologics, Inc. Presents at Boston CEO Conference, Jun-04-2014 05:00 PM
Jun 2 14
Avaxia Biologics, Inc. Presents at Boston CEO Conference, Jun-04-2014 05:00 PM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, Massachusetts, United States. Speakers: Barbara S. Fox, Founder and Chief Executive Officer.
Similar Private Companies By Industry
Recent Private Companies Transactions
April 22, 2014